Preclinical Development of ADCT-601, a Novel Pyrrolobenzodiazepine Dimer-based Antibody–drug Conjugate Targeting AXL-expressing Cancers

AXL, a tyrosine kinase receptor that is overexpressed in many solid and hematologic malignancies, facilitates cancer progression and is associated with poor clinical outcomes. Importantly, drug-induced expression of AXL results in resistance to conventional chemotherapy and targeted therapies. Toget...

Descripción completa

Detalles Bibliográficos
Autores principales: Zammarchi, Francesca, Havenith, Karin EG., Chivers, Simon, Hogg, Paul, Bertelli, Francois, Tyrer, Peter, Janghra, Narinder, Reinert, Halla W., Hartley, John A., van Berkel, Patrick H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Large Molecule Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377743/
https://www.ncbi.nlm.nih.gov/pubmed/35086955
http://dx.doi.org/10.1158/1535-7163.MCT-21-0715

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377743/
https://www.ncbi.nlm.nih.gov/pubmed/35086955
http://dx.doi.org/10.1158/1535-7163.MCT-21-0715

Ejemplares similares